annb0t
Top 20
As an investor its worth striving to ensure your overall portfolio beats the market average. But the risk of stock picking is that you will likely buy under-performing companies. We regret to report that long term Clinuvel Pharmaceuticals Limited (ASX:CUV) shareholders have had that experience, with the share price dropping 38% in three years, versus a market return of about 29%. The more recent news is of little comfort, with the share price down 25% in a year. More recently, the share price ha...
>>> Read more: Clinuvel Pharmaceuticals (ASX:CUV) shareholders have endured a 38% loss from investing in the stock three years ago
>>> Read more: Clinuvel Pharmaceuticals (ASX:CUV) shareholders have endured a 38% loss from investing in the stock three years ago
